Actively Recruiting
OMAR Opioid Use Disorder
Led by Yale University · Updated on 2026-04-28
30
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
CONDITIONS
Official Title
OMAR Opioid Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide informed consent
- Male and female 18 years and older
- DSM-5 diagnosis of opioid use disorder (for OUD group)
- Physically healthy with no clinically unstable medical conditions
- Written informed consent and ability to comply with study procedures
You will not qualify if you...
- Current neuro-psychiatric illness or severe systemic disease (except opioid use disorder in OUD group)
- Presence of ferromagnetic metal in the body or a heart pacemaker
- Prior exposure to ionizing radiation exceeding recommended limits when combined with study tracer
- Claustrophobia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Connecticut Mental Health Center, Clinical Neuroscience Research Unit
New Haven, Connecticut, United States, 06519
Actively Recruiting
Research Team
A
Anahita Bassir Nia, MD
CONTACT
A
Angelina Contreras
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here